Literature DB >> 3168722

Retinal toxicity of antibiotics: evaluation by electroretinogram.

K Mochizuki1, M Torisaki, K Kawasaki, Y Shirao, Y Yamashita, K Kitano, D Yonemura.   

Abstract

Toxicity of an intravitreal injection of gentamicin sulfate, disodium sulbenicillin and cefazolin sodium on the retina was investigated by electroretinogram in albino and pigmented rabbits. Recordings were made before injection and 2 hours and 3, 7, 14, and 21 days after injection. Significant differences were found in the susceptibility of the electroretinogram components to various antibiotics as follows. Gentamicin 0.24 mg/0.1 ml irreversibly abolished all the components examined. Sulbenicillin 4.0, 8.0, or 12 mg/0.1 ml transiently suppressed the b-wave and the oscillatory potentials incrementally with increasing dose. Cefazolin 0.5, 2.0, or 5.0 mg/0.1 ml selectively reduced the oscillatory potentials, leaving the a- and b-waves almost unattenuated. The cefazolin-suppressed oscillatory potentials recovered within 14 days after injection. Judging from the most susceptible electroretinogram components to each antibiotic, we recommend intravitreal doses of these antibiotics for clinical use as follows: gentamicin 0.1 mg/0.1 ml, sulbenicillin 2 mg/0.1 ml, and cefazolin 0.25 mg/0.1 ml.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3168722     DOI: 10.1007/bf00153701

Source DB:  PubMed          Journal:  Doc Ophthalmol        ISSN: 0012-4486            Impact factor:   2.379


  15 in total

1.  Macular infarction after endophthalmitis treated with vitrectomy and intravitreal gentamicin.

Authors:  B P Conway; P A Campochiaro
Journal:  Arch Ophthalmol       Date:  1986-03

2.  Retinal toxicity of intravitreal gentamicin. An electron microscopic study.

Authors:  D J D'Amico; J Libert; K R Kenyon; L A Hanninen; L Caspers-Velu
Journal:  Invest Ophthalmol Vis Sci       Date:  1984-05       Impact factor: 4.799

3.  Toxicity of intravitreal aminoglycosides in primates.

Authors:  T O Bennett; G A Peyman
Journal:  Can J Ophthalmol       Date:  1974-10       Impact factor: 1.882

4.  Intravitreal injection of cephaloridine in the treatment of endophthalmitis.

Authors:  R O Graham; G A Peyman; G Fishman
Journal:  Arch Ophthalmol       Date:  1975-01

5.  Ketamine hydrochloride: an effective general anesthetic for use in electroretinography.

Authors:  D Sasovetz
Journal:  Ann Ophthalmol       Date:  1978-11

6.  Experimental intravitreal gentamicin.

Authors:  I G Zachary; R K Forster
Journal:  Am J Ophthalmol       Date:  1976-10       Impact factor: 5.258

7.  Postoperative endophthalmitis: a comparison of methods for treatment and prophlaxis with gentamicin.

Authors:  G A Peyman; J T Paque; H I Meisels; T O Bennett
Journal:  Ophthalmic Surg       Date:  1975

8.  Toxicity, efficacy, and clearance of intravitreally injected of cefazolin.

Authors:  J P Fisher; S E Civiletto; R K Forster
Journal:  Arch Ophthalmol       Date:  1982-04

9.  Infectious endophthalmitis. Review of 36 cases.

Authors:  C A Puliafito; A S Baker; J Haaf; C S Foster
Journal:  Ophthalmology       Date:  1982-08       Impact factor: 12.079

10.  The intravitreal use of carbenicillin (Geopen) for treatment od pseudomonas endophthalmitis.

Authors:  A G Schenk; G A Peyman; J T Paque
Journal:  Acta Ophthalmol (Copenh)       Date:  1974
View more
  2 in total

1.  Retinal function assessed by ERG before and after induction of ocular aspergillosis and treatment by the anti-fungal, micafungin, in rabbits.

Authors:  Joseph M Harrison; Randolph D Glickman; Charles S Ballentine; Yolanda Trigo; Melanie A Pena; Pearl Kurian; Laura K Najvar; Neeru Kumar; Ankit H Patel; William E Sponsel; John R Graybill; William C Lloyd; Margaret M Miller; Gianmarco Paris; Fernando Trujillo; Aaron Miller; Robert Melendez
Journal:  Doc Ophthalmol       Date:  2005-01       Impact factor: 2.379

2.  Antibiotics and light responses in superfused bovine retina.

Authors:  P Walter; C Lüke; W Sickel
Journal:  Cell Mol Neurobiol       Date:  1999-02       Impact factor: 5.046

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.